Long Term Survival and Continued CompleteResponse of Vemurafenib in a Metastatic MelanomaPatient with BRAF V600K Mutation

BRAF kinase inhibitors such as Vemurafenib have shown improvement in overall survival, progression-free survival,and response rates in patients with metastatic melanoma with BRAF V600K mutation. However, there were no cases of completeremission reported in patients with V600K mutation before.Case Presentation. A 53-year-old man with metastatic melanoma anddialysis dependent end stage renal failure was treated safely with Vemurafenib for a BRAF V600K mutation positive melanomaand the case was reported elsewhere. After a long follow-up of the same patient treated with Vemurafenib, a complete radiologicalresponse was observed and the renal functions remained stable throughout the treatment. Main toxicities reported were grade1 photosensitivity and skin cancers. Vemurafenib was discontinued but patient remains disease free 12 months after stoppingtreatment and the clinical review is ongoing.Conclusion. This is the first reported case of complete radiological response to a BRAFinhibitor in metastatic melanoma with BRAF V600K mutation and remains disease free even after discontinuation of treatment.This also shows clinical safety of Vemurafenib in end stage renal failure and highlights the need for closer look at the subgroup ofpatients with BRAF V600K mutation and its tumour biology.